Loading…
Based on limited metadata without access to the full warning letter text, Medinatura Inc., a drug manufacturer, received an FDA warning letter on June 11, 2020. While the specific violation details are unavailable, the warning letter indicates regulatory concerns regarding the company's drug products or manufacturing practices. The FDA's issuance of this letter indicates the company failed to meet applicable federal drug regulations, though the exact nature and scope of violations cannot be determined from the metadata provided.